CJC-1295 with DAC 2mgCJC-1295 with DAC 2mg
An albumin-binding GHRH analogue studied in small human trials for hormonal responses, not proven wellness outcomes.
Answer a short online consultation. A clinician reviews it, and you only pay if treatment is approved. Dispensed by our licensed facility.
What it is
CJC-1295 with DAC is a synthetic growth hormone-releasing hormone analogue containing a drug affinity complex. This modification enables binding to circulating albumin.
Albumin binding prolongs exposure and can sustain changes in growth hormone and IGF-1. A longer hormonal effect is a pharmacological property, not evidence of an anti-ageing benefit.
Why people ask about it
People ask about prolonged growth hormone signalling and body composition, often confusing biochemical changes with meaningful health outcomes.
What the science says
A 2006 study in healthy adults reported increases in growth hormone and IGF-1 after CJC-1295 exposure. The small, short-duration studies were not designed to establish improved longevity, physical performance or long-term cardiovascular safety.
Is it right for me?
For CJC-1295 with DAC, online consultation and clinician approval are required before payment, with attention to prolonged endocrine exposure and baseline health.
How Welcuren works
Complete a short online consultation about your health and goals.
A clinician reviews your answers, may ask follow-up questions, and decides whether this treatment is appropriate for you.
You only pay once treatment is approved. Our licensed facility then dispatches it with full instructions, on tracked global delivery.
Safety
Flushing, headache and injection-site reactions have been reported, and glucose disturbance or fluid retention are concerns with growth hormone-axis stimulation. Active malignancy, pituitary disorders, pregnancy and breastfeeding require review; your clinician will advise
Questions
What is DAC intended to change?
The drug affinity complex supports albumin binding and extends the molecule’s persistence.
What did the healthy-adult study measure?
Its key findings concerned growth hormone and IGF-1 concentrations rather than established wellness outcomes.
Is a higher IGF-1 level always desirable?
IGF-1 must be interpreted clinically; an increase alone does not establish improved health.
Is this equivalent to No DAC material?
The albumin-binding modification makes it pharmacologically distinct from products sold without DAC.
This information is educational and not a substitute for advice from your clinician. Prescription treatments are only supplied after a clinical consultation.
Often considered together
Many clients start with a blood test so their clinician has a full picture.
AOD-9604 5mgAOD-9604 5mg
AOD-9604 5mg is supplied in a branded pre-filled pen with case, available only following an online consultation and clinician approval.
CJC-1295 + Ipamorelin BlendCJC-1295 + Ipamorelin Blend
A dual-secretagogue blend with uncertain formulation and no robust clinical evidence for the marketed combination.
CJC-1295 No DAC 5mgCJC-1295 No DAC 5mg
A label commonly used for modified GRF(1–29), distinct from the albumin-binding CJC-1295 studied in published trials.